Doetinchem Cohort Study – National Institute for Public Health and the Environment

The Doetinchem Cohort Study is a population based cohort, focussed on lifestyle and chronic diseases. About 6,000 individuals aged 20-59 years entered the study during 1987-1991, and are re-examined every five years. For each round of investigation biological samples (plasma, serum, buffy coats) have been stored.

Key facts

Name of the connected EIT Health partner:
Number of individuals: 6000
Biobank confirmed willingness to provide samples/data for EIT Health studies: Yes, but not private industry
Contact person(s) and contact data
(e-mail address, tel. no) for access purposes:
Monique Verschuren (PI),, +31 33 2743508;  Susan Picavet (project leader),, +31 33 2743063
Number of samples:
Sample type: Buffy Coat; Plasma; Serum; Urine; DNA

General information

Type of biobank: Population; Longitudinal
If longitudinal the frequency: Every 5 years
Link to central portal to seek samples and data:
Broad consent: Yes
Option to recall donors: Yes
Option to recall family members: No

Biobank access procedure:

Major terms for access: Contact the principal investigator.
Ethical and legal compliance: Approved by medical ethics committee
Speed and reliability of delivery: Depending on the nature of the collaboration, we ask a lumpsum contribution to maintenance of the data collection up to 5 kE, and (if needed) the costs for datamanagement/retrieval.’

Quality management system:

Storage: A total of 25 ml of non-fasting venous blood is collected in every round using three types of vacutainers: NaF, serum and EDTA. Samples are centrifuged and aliquoted in 25 cryovial tubes, including plasma, serum, erythrocytes and buffy coat. Standard storage is at -80˚ C. Blood samples are available for all participants for all rounds, though there are some differences per measurement round refer-ring to storage conditions (in round 1 only -20˚ C, and additional -196˚ C storage in round 2 only) or number of tubes. From round 5 onwards we took spot urine samples and stored those at -80˚ C, after testing the sample for urinary tract infection.
Compliance with international standards:
Current ISO certificates:


Clinical data linked to samples: Questionnaire data; Clinical data; GWAS; Height, weight, blood pressure (arm and ankle), lung function, waist and hip circumference, heel bone mass (from round 5 onwards), AGEs (from round 6 onwards), hand grip test/balance test/chair test (from round 5 onwards), cognitive functioning; mortality, hospital discharge by diagnosis, cancer registere, pharmacy register
Data standards:
Data security rules:

Biobank related service:

Research support, what type of expertise?:
Core facility services; what type? Link?:
Queries from national health registers:
Links to the model contract and MTA:


IP rules, what is negotiable?:
Requirements to study results (access etc.):
Participant’s right to the information:
Number of access contracts with industry:

COVID-19 samples:

Access to biological samples from patients with COVID-19?

  • Serum
  • Full blood (for RNA extraction)
  • EDTA-Full blood (for DNA extraction)
  • EDTA-Plasma
  • Citrate-Plasma
  • PBMC (Peripheral Blood Mononuclear Cells)
  • Nasopharyngeal aspirate
  • Tracheal aspirate
Contact person(s) and contact data (e-mail address, tel. no) for access purposes

The "Registers and Biobanks in Transition” strategic initiative is funded by EIT Health